Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Ludwig A. Hothorn (Leibniz University Hannover, Germany)
Chair:
Dr. Bernd-Wolfgang Igl (Bayer AG)
Abstract:
Dose-response analysis is a central part in statistical evaluation of toxicological bioassays. Two approaches are used: simultaneous testing of order-restricted multiple contrasts and regression-based modeling. The first one considers the DOSE qualitatively, i.e. as randomized factor whereas the second assumes DOSE as quantitative covariate (in bioassays commonly for grouped dose levels). Both approaches are demonstrated by means of real data examples where robustness, e.g. against downturn effects is discussed. Moreover, a new approach is explained, where DOSE is jointly considered both quali- and quantitatively.
The recent p-value controversy is discussed from the perspective of regulatory toxicology where first confidence intervals for specific selected effect sizes are recommended. Secondly, the inclusion of individual data points within or without a prediction interval is proposed as an alternative to common-used null-hypothesis significance tests. The prediction intervals are defined for any single future value of a group with sample size n_i using the controls of multiple historical bioassays. The within- and between assay variance is considered by a mixed effect model.
Finally, the question will be discussed why the proof of safety („be safe in negative results“) is not widely used in routine up to now.
The “third main set” of statistics is: software must be available. And therefore all methods are demonstrated using //R-//CRAN packages.
Registration:
This webinar will take place from 14:00 - 15:00 and is free to attend.
Registration has now closed.
Upcoming Events
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
PSI Training Course: Regulatory Guidelines for Statisticians
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK